FDA warns Chara Biologics over unapproved, unlicensed CharaExo, CharaCore, CharaOmni.
What happened
FDA inspected Chara Biologics’ Chatsworth, CA facility from July 23 to August 16, 2024, and reviewed the firm’s websites, brochures, and physician materials. FDA found CharaExo, CharaCore, and CharaOmni promoted for many diseases without an approved BLA or IND, plus CGMP/CGTP violations and unsupported expiration-date extensions for CharaExo.
What FDA found
FDA says the products are unapproved new drugs and unlicensed biological products because no BLA or IND is in effect.
FD&C Act section 505(a), 21 U.S.C. § 355(a); PHS Act section 351(a)(1), 42 U.S.C. § 262(a)(1)FDA says the firm lacked a quality unit with authority to approve or reject labeling and drug products and lacked written quality-unit procedures.
21 CFR 211.22(a) and 211.22(d)FDA says Chara did not keep donor-eligibility determination records, including the responsible person’s name and the date, for umbilical cord donors.
21 CFR 1271.55(d)(1)(iii)FDA says CharaExo labeling was false or misleading because the firm extended expiration dates by one year or more without supporting data.
FD&C Act section 502(a), 21 U.S.C. § 352(a)FDA says CharaCore and CharaOmni failed HCT/P criteria for minimal manipulation and homologous use, so they are regulated as drugs and biological products.
21 CFR 1271.10(a)(1), (a)(2); 21 CFR 1271.3(f)(1), (c)
What FDA wants
FDA asks Chara to respond in writing within 15 working days with specific corrective steps, documentation, and plans for inventory and distributed products. If it cannot meet that timeframe, it must explain the delay and give a completion date.
Who should pay attention
- clinics and physicians buying or using Chara products
- brands that buy or distribute HCT/P or biologic products from contract manufacturers
- quality teams managing donor eligibility and labeling for cell/tissue products
This is a summary. Read the original letter on fda.gov.